Inhibikase Therapeutics (Inhibikase Therapeutics) Cash-to-Debt : 46.65 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Inhibikase Therapeutics's cash to debt ratio for the quarter that ended in Mar. 2024 was 46.65.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Inhibikase Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Inhibikase Therapeutics's Cash-to-Debt or its related term are showing as below:

IKT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 62.34 Max: No Debt
Current: 46.65

During the past 6 years, Inhibikase Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 62.34.

IKT's Cash-to-Debt is ranked better than
71.11% of 1478 companies
in the Biotechnology industry
Industry Median: 7.005 vs IKT: 46.65

Inhibikase Therapeutics Cash-to-Debt Historical Data

The historical data trend for Inhibikase Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Inhibikase Therapeutics Cash-to-Debt Chart

Inhibikase Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.05

43.74

163.66

65.67

55.22

Inhibikase Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															79.13	70.25	62.34	55.22	46.65

Competitive Comparison of Inhibikase Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Inhibikase Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Inhibikase Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibikase Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Inhibikase Therapeutics's Cash-to-Debt falls into.

Inhibikase Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Inhibikase Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	13.252	/	(0.15	+	0.09)
	=	55.22

Inhibikase Therapeutics's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.749	/	(0.151	+	0.058)
	=	46.65

Inhibikase Therapeutics (NAS:IKT) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Inhibikase Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Inhibikase Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Inhibikase Therapeutics (Inhibikase Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339

Website

https://www.inhibikase.com

Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.

Executives

Paul C Grint	director	7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman	director	9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman	director	256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion	director	C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner	director, 10 percent owner, officer: President and CEO	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli	officer: Cheif Financial Officer
Elizabeth G. O'farrell	director	932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman	10 percent owner	3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339